GlassScriptPhysician profile
Hamza Aziz
NPI 1306230362
$5,071.62
in general payments reported to CMS, 2019-2025
22 companies · $238 in 2025
The $238 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,268 · 2021: $739 · 2022: $337 · 2023: $1,221 · 2024: $269 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $938 · Travel and Lodging: $789.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $937.98 |
| Travel and Lodging | $789.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $2,036.40 | 2019 | |
| Atricure, INC. | $845.31 | 2019-2023 | |
| Abbvie INC. | $544.49 | 2021-2024 | Mavyret, Rinvoq, Linzess |
| Cook Medical LLC | $415.76 | 2019-2021 | |
| Janssen Biotech, INC. | $209.62 | 2021-2025 | Tremfya, Stelara |
| Abbott Laboratories | $170.82 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.99 | 2022 | |
| Janssen Scientific Affairs, LLC | $113.29 | 2021 | |
| Intercept Pharmaceuticals, INC. | $85.17 | 2021-2023 | Ocaliva |
| Gilead Sciences, INC. | $77.52 | 2021-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $71.62 | 2021-2022 | |
| Qol Medical, LLC | $70.07 | 2022-2024 | Sucraid, Sucraid |
| Agiliti Surgical, INC. | $59.84 | 2024 | Koelis Trinity Fusion Biopsy System, Sonablate Hifu |
| Genzyme Corporation | $53.46 | 2025 | |
| Celgene Corporation | $38.64 | 2023 | Zeposia |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $33.26 | 2024 | Hillrom - Carnation Ambulatory Monitor |
| Pfizer INC. | $29.46 | 2025 | |
| Alcresta Therapeutics, INC. | $21.30 | 2023 | Relizorb |
| Daiichi Sankyo INC. | $21.28 | 2021 | |
| Medtronic, INC. | $21.20 | 2025 | Nexpowder |
| Astrazeneca Pharmaceuticals LP | $14.15 | 2021 | |
| Ardelyx, INC. | $13.97 | 2024 | Ibsrela |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamza Aziz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.